Tango Therapeutics nets $60m Series B
Cambridge, Massachusetts-based Tango Therapeutics, a biotechnology company focused on targeted cancer therapies, has secured $60 million in Series B financing.
Cambridge, Massachusetts-based Tango Therapeutics, a biotechnology company focused on targeted cancer therapies, has secured $60 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination